Calley A. Middleton
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.
Journal: The Journal of antimicrobial chemotherapy
Published: November 19, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Journal: Nature communications
Published: October 11, 2024
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Journal: Nature communications
Published: September 26, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Journal: The Lancet. Infectious diseases
Published: July 14, 2022
Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons.
Journal: Journal of Parkinson's disease
Published: July 12, 2021
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: June 12, 2021
Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease.
Journal: NPJ Parkinson's disease
Published: May 31, 2017
Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy.
Journal: Human molecular genetics
Published: February 12, 2013
parkin-induced defects in neurophysiology and locomotion are generated by metabolic dysfunction and not oxidative stress.
Journal: Human molecular genetics
Published: January 05, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026